Julia Kirchheiner

Summary

Affiliation: University of Ulm
Country: Germany

Publications

  1. pmc Drug monitoring in child and adolescent psychiatry for improved efficacy and safety of psychopharmacotherapy
    Claudia Mehler Wex
    TDM Laboratory, Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University of Wuerzburg, Fuechsleinstr 5, 97080 Wuerzburg, Germany
    Child Adolesc Psychiatry Ment Health 3:14. 2009
  2. ncbi Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes
    Julia Kirchheiner
    Department of Pharmacology of Natural Products and Clinical Pharmacology, University of Ulm, Helmholtzstr 20, 89081 Ulm, Germany
    Biochim Biophys Acta 1770:489-94. 2007
  3. doi Cytochrome P450 2D6 genotyping: potential role in improving treatment outcomes in psychiatric disorders
    Julia Kirchheiner
    Institute of Pharmacology of Natural Products and Clinical Pharmacology, University of Ulm, Ulm, Germany
    CNS Drugs 23:181-91. 2009
  4. doi Relative potency of proton-pump inhibitors-comparison of effects on intragastric pH
    Julia Kirchheiner
    Institute of Pharmacology of Natural Products and Clinical Pharmacology, University of Ulm, Helmholtzstr 20, 89081 Ulm, Germany
    Eur J Clin Pharmacol 65:19-31. 2009
  5. doi Genetic variants in FKBP5 affecting response to antidepressant drug treatment
    Julia Kirchheiner
    Institute of Pharmacology of Natural Products and Clinical Pharmacology, University of Ulm, Helmholtzstr 20, 89081 Ulm, Germany
    Pharmacogenomics 9:841-6. 2008
  6. ncbi Impact of genetic polymorphisms in CYP2C8 and rosiglitazone intake on the urinary excretion of dihydroxyeicosatrienoic acids
    Julia Kirchheiner
    Institute of Pharmacology of Natural Products and Clinical Pharmacology, University Ulm, Helmholtzstr 20, 89081 Ulm, Germany
    Pharmacogenomics 9:277-88. 2008
  7. ncbi A 40-basepair VNTR polymorphism in the dopamine transporter (DAT1) gene and the rapid response to antidepressant treatment
    J Kirchheiner
    Department of Pharmacology of Natural Products and Clinical Pharmacology, University of Ulm, Ulm, Germany
    Pharmacogenomics J 7:48-55. 2007
  8. ncbi Effects of the CYP2D6 gene duplication on the pharmacokinetics and pharmacodynamics of tramadol
    Julia Kirchheiner
    Institute of Clinical Pharmacology, Charite University Medicine, Berlin, Germany
    J Clin Psychopharmacol 28:78-83. 2008
  9. ncbi Contribution of allelic variations in transporters to the phenotype of drug response
    Julia Kirchheiner
    Department of Pharmacology of Natural Products and Clinical Pharmacology, University of Ulm, Ulm, Germany
    J Psychopharmacol 20:27-32. 2006
  10. ncbi CYP2D6 phenotype prediction from genotype: which system is the best?
    J Kirchheiner
    Institute of Pharmacology of Natural Products and Clinical Pharmacology, University of Ulm, Ulm, Germany
    Clin Pharmacol Ther 83:225-7. 2008

Collaborators

Detail Information

Publications69

  1. pmc Drug monitoring in child and adolescent psychiatry for improved efficacy and safety of psychopharmacotherapy
    Claudia Mehler Wex
    TDM Laboratory, Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University of Wuerzburg, Fuechsleinstr 5, 97080 Wuerzburg, Germany
    Child Adolesc Psychiatry Ment Health 3:14. 2009
    ....
  2. ncbi Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes
    Julia Kirchheiner
    Department of Pharmacology of Natural Products and Clinical Pharmacology, University of Ulm, Helmholtzstr 20, 89081 Ulm, Germany
    Biochim Biophys Acta 1770:489-94. 2007
    ..A controlled prospective clinical trial with one arm receiving genotype-based dose adjustments and the other arm receiving therapy as usual will elucidate the benefit of pharmacogenomics-based individualization of certain drug therapies...
  3. doi Cytochrome P450 2D6 genotyping: potential role in improving treatment outcomes in psychiatric disorders
    Julia Kirchheiner
    Institute of Pharmacology of Natural Products and Clinical Pharmacology, University of Ulm, Ulm, Germany
    CNS Drugs 23:181-91. 2009
    ..However, routine application of pharmacogenetic dose adjustment in clinical practice requires prospective validation...
  4. doi Relative potency of proton-pump inhibitors-comparison of effects on intragastric pH
    Julia Kirchheiner
    Institute of Pharmacology of Natural Products and Clinical Pharmacology, University of Ulm, Helmholtzstr 20, 89081 Ulm, Germany
    Eur J Clin Pharmacol 65:19-31. 2009
    ..Here we derived PPI dose equivalents based on a comprehensive assessment of dose-dependent effects on intragastric pH...
  5. doi Genetic variants in FKBP5 affecting response to antidepressant drug treatment
    Julia Kirchheiner
    Institute of Pharmacology of Natural Products and Clinical Pharmacology, University of Ulm, Helmholtzstr 20, 89081 Ulm, Germany
    Pharmacogenomics 9:841-6. 2008
    ..We aimed to analyze whether these findings could be reproduced in a different sample of otherwise comparable inpatients with major depression...
  6. ncbi Impact of genetic polymorphisms in CYP2C8 and rosiglitazone intake on the urinary excretion of dihydroxyeicosatrienoic acids
    Julia Kirchheiner
    Institute of Pharmacology of Natural Products and Clinical Pharmacology, University Ulm, Helmholtzstr 20, 89081 Ulm, Germany
    Pharmacogenomics 9:277-88. 2008
    ..It is unknown how genetic polymorphisms affect formation of these diuretic, vasodilatory and anti-inflammatory eicosanoids, and whether the CYP2C8 substrate rosiglitazone inhibits their formation...
  7. ncbi A 40-basepair VNTR polymorphism in the dopamine transporter (DAT1) gene and the rapid response to antidepressant treatment
    J Kirchheiner
    Department of Pharmacology of Natural Products and Clinical Pharmacology, University of Ulm, Ulm, Germany
    Pharmacogenomics J 7:48-55. 2007
    ..6 (95% CI 0.8-3.2) and carriers of the 9/9 genotype had an OR of 6.0 (1.5-24.4) for no or poor response. Further studies are required to confirm this clinical association and to elucidate the underlying mechanisms...
  8. ncbi Effects of the CYP2D6 gene duplication on the pharmacokinetics and pharmacodynamics of tramadol
    Julia Kirchheiner
    Institute of Clinical Pharmacology, Charite University Medicine, Berlin, Germany
    J Clin Psychopharmacol 28:78-83. 2008
    ..Therefore, tramadol may frequently cause adverse effects in southern European and Northern African populations with a high proportion of UMs...
  9. ncbi Contribution of allelic variations in transporters to the phenotype of drug response
    Julia Kirchheiner
    Department of Pharmacology of Natural Products and Clinical Pharmacology, University of Ulm, Ulm, Germany
    J Psychopharmacol 20:27-32. 2006
    ..So far, transporter genotypes are not yet eligible for individual prediction of drug response...
  10. ncbi CYP2D6 phenotype prediction from genotype: which system is the best?
    J Kirchheiner
    Institute of Pharmacology of Natural Products and Clinical Pharmacology, University of Ulm, Ulm, Germany
    Clin Pharmacol Ther 83:225-7. 2008
    ..Thus, a more favorable tamoxifen treatment seems to be feasible through a priori genetic assessment of CYP2D6...
  11. ncbi [State of the art of pharmacogenetic diagnostics in drug therapy]
    J Kirchheiner
    Klinische Pharmakologie, Abteilung Naturheilkunde and Klinische Pharmakologie, Universitat Ulm, Heimholtzstrasse 20, 89081 Ulm, BRD
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 49:995-1003. 2006
    ....
  12. ncbi Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype
    Julia Kirchheiner
    Institute of Pharmacology of Natural Products and Clinical Pharmacology, University of Ulm, Germany
    Clin Pharmacol Ther 80:657-67. 2006
    ..The purpose of this was to clarify the role of this polymorphism with regard to the pharmacokinetics and clinical effects of rosiglitazone...
  13. ncbi Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication
    J Kirchheiner
    Department of Pharmacology of Natural Products and Clinical Pharmacology, University Ulm, Ulm, Germany
    Pharmacogenomics J 7:257-65. 2007
    ..It might be good if physicians would know about the CYP2D6 duplication genotype of their patients before administering codeine...
  14. ncbi Pharmacogenetics in psychiatry--a useful clinical tool or wishful thinking for the future?
    Julia Kirchheiner
    Institute of Pharmacology of Natural Products and Clinical Pharmacology, University Ulm, Helmholtzstr 20, 890181 Ulm, Germany
    Curr Pharm Des 16:136-44. 2010
    ..Here, we review the potential impact of an integrated approach, including the assessment of intermediate phenotypes for the effect of genetic polymorphism, the monitoring of therapy progress, and response prediction in depression...
  15. doi CYP2D6 in the brain: genotype effects on resting brain perfusion
    J Kirchheiner
    Institute of Pharmacology of Natural Products and Clinical Pharmacology, University of Ulm, Ulm, Germany
    Mol Psychiatry 16:237, 333-41. 2011
    ..An exploratory analysis, extended to the whole brain, suggested the involvement of CYP2D6 in regions associated with alertness or serotonergic function. These findings support the hypothesis of a functional role of CYP2D6 in the brain...
  16. ncbi Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers
    Julia Kirchheiner
    Institute of Clinical Pharmacology and the Department of Endocrinology, University Medical Center Charite, Humboldt University, Berlin, Germany
    Clin Pharmacol Ther 71:286-96. 2002
    ..We explored the impact of these polymorphisms on glyburide pharmacokinetics and the effects on insulin and glucose concentrations...
  17. ncbi Influence of CYP2C9 and CYP2D6 polymorphisms on the pharmacokinetics of nateglinide in genotyped healthy volunteers
    Julia Kirchheiner
    Institute of Clinical Pharmacology, University Medical Center Charite, Humboldt University Berlin, Berlin, Germany
    Clin Pharmacokinet 43:267-78. 2004
    ..According to in vitro data, about 70% of nateglinide intrinsic clearance may be mediated by cytochrome P450 (CYP) 2C9 and a smaller fraction by CYP3A4 and CYP2D6...
  18. ncbi Effects of polymorphisms in CYP2D6, CYP2C9, and CYP2C19 on trimipramine pharmacokinetics
    Julia Kirchheiner
    Institute of Clinical Pharmacology, University Medical Center Charite, Humboldt University of Berlin, Berlin, Germany
    J Clin Psychopharmacol 23:459-66. 2003
    ..This indicates that both CYP2C enzymes contribute to the demethylation of desmethyltrimipramine and CYP2D6 to further metabolism...
  19. ncbi Enantiospecific pharmacokinetics of metoprolol in CYP2D6 ultra-rapid metabolizers and correlation with exercise-induced heart rate
    Angela Seeringer
    Institute of Pharmacology of Natural Products and Clinical Pharmacology, University of Ulm, Ulm, Germany
    Eur J Clin Pharmacol 64:883-8. 2008
    ....
  20. ncbi Impact of the CYP2D6 ultra-rapid metabolizer genotype on doxepin pharmacokinetics and serotonin in platelets
    Julia Kirchheiner
    Institute of Clinical Pharmacology, Laboratory of Clinical Neurobiology, Charite University Medicine, Berlin, Germany
    Pharmacogenet Genomics 15:579-87. 2005
    ..We studied the effect of the CYP2D6 duplication genotype on doxepin pharmacokinetics and platelet serotonin uptake and concentrations...
  21. ncbi Enantiospecific effects of cytochrome P450 2C9 amino acid variants on ibuprofen pharmacokinetics and on the inhibition of cyclooxygenases 1 and 2
    Julia Kirchheiner
    Institute of Clinical Pharmacology, Charite, Humboldt University, Berlin, Germany
    Clin Pharmacol Ther 72:62-75. 2002
    ..In humans, there are 2 variants of CYP2C9 with a high population frequency. We studied their impact on ibuprofen pharmacokinetics and on the inhibition of cyclooxygenases 1 and 2...
  22. ncbi Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers
    Julia Kirchheiner
    Institute of Clinical Pharmacology, University Medical Center Charite, Humboldt University Berlin, Berlin, Germany
    Pharmacogenetics 12:571-80. 2002
    ..The CYP2D6 polymorphism had a major impact on E-doxepin pharmacokinetics and CYP2D6 PMs might be at an elevated risk for adverse drug effects when treated with common recommended doses...
  23. ncbi Influence of CYP2C9 genetic polymorphisms on pharmacokinetics of celecoxib and its metabolites
    Julia Kirchheiner
    Institute of Clinical Pharmacology, Charite, Humboldt University of Berlin, Schumannstrasse 20 21, 10098 Berlin, Germany
    Pharmacogenetics 13:473-80. 2003
    ..It remains to be shown whether this is associated with greater efficacy or with an increased incidence and severity of adverse events...
  24. ncbi Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics
    Julia Kirchheiner
    Institute of Clinical Pharmacology, Humboldt University, Berlin, Germany
    Clin Pharmacol Ther 76:302-12. 2004
    ..We compared metoprolol pharmacokinetics and effects in UMs with extensive metabolizers (EMs) and with poor metabolizers (PM) as an additional reference group...
  25. ncbi Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers
    Julia Kirchheiner
    Institute of Clinical Pharmacology, Charite, Humboldt University of Berlin, Berlin, Germany
    Clin Pharmacol Ther 74:186-94. 2003
    ..The consequences of CYP2C9 genetic polymorphisms on fluvastatin pharmacokinetics and on its efficacy have not been investigated in humans thus far...
  26. pmc Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: no relationship to the CYP2C9 genetic polymorphism in humans
    Julia Kirchheiner
    Institute of Clinical Pharmacology, University Medical Centre Charité, Humboldt University, Berlin, Germany
    Br J Clin Pharmacol 55:51-61. 2003
    ..As a surrogate marker of diclofenac activity, the ex vivo formation of prostaglandin E2 and thromboxane B2, which reflects COX-2 and COX-1 activity, was measured...
  27. ncbi Impact of the CYP2D6 ultrarapid metabolizer genotype on mirtazapine pharmacokinetics and adverse events in healthy volunteers
    Julia Kirchheiner
    Institute of Clinical Pharmacology, Humboldt University Berlin, Germany
    J Clin Psychopharmacol 24:647-52. 2004
    ..We hypothesized that ultrarapid metabolizers (defined as carriers of the CYP2D6 gene duplication plus another functional allele) have a risk for therapeutic failure due to too low tissue concentrations...
  28. doi Serotonin transporter gene and response to lithium augmentation in depression
    Thomas J Stamm
    Department of Psychiatry and Psychotherapy, Charite Universitatsmedizin Berlin, Campus Charite Mitte, Berlin, Germany
    Psychiatr Genet 18:92-7. 2008
    ..Lithium augmentation is a well-established strategy for overcoming treatment resistance. In this study, the 5-HTTLPR allele variant's effect on lithium augmentation was analyzed in antidepressant-nonresponsive patients...
  29. ncbi Implications of pharmacogenetics for individualizing drug treatment and for study design
    Christian Meisel
    Institute of Clinical Pharmacology, Berlin Center for Genome Based Bioinformatics, University Hospital Charite, Humboldt University of Berlin, Schumannstrasse 20 21, 10098 Berlin, Germany
    J Mol Med (Berl) 81:154-67. 2003
    ....
  30. ncbi Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6
    Julia Kirchheiner
    Institute of Clinical Pharmacology, University Medical Center Charite, Humboldt University, Berlin, Germany
    Pharmacogenetics 13:619-26. 2003
    ..The role of this allele should also be studied in other CYP2B6 substrates, including cyclophosphamide, halothane, mianserin, promethazine and propofol...
  31. ncbi Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance
    Julia Kirchheiner
    Institute of Clinical Pharmacology, University Medical Center Charite, Humboldt University, Berlin, Germany
    Clin Pharmacokinet 44:1209-25. 2005
    ....
  32. ncbi Effects of CYP2C9 polymorphisms on the pharmacokinetics of R- and S-phenprocoumon in healthy volunteers
    Julia Kirchheiner
    Institute of Clinical Pharmacology, Charite, Humboldt University of Berlin, Germany
    Pharmacogenetics 14:19-26. 2004
    ..However, regarding phenprocoumon hydroxylation CYP2C9 genotypes had only marginal effects on S- and R-phenprocoumon total clearance in healthy volunteers...
  33. ncbi Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers
    Julia Kirchheiner
    Institute of Clinical Pharmacology, University Medical Center Charite, Humboldt University, Berlin, Germany
    Pharmacogenetics 12:101-9. 2002
    ..The pronounced differences in pharmacokinetics due to the amino acid variants did not significantly affect plasma insulin and glucose concentrations in healthy volunteers...
  34. ncbi Cytochrome p450 3A4 messenger ribonucleic acid induction by rifampin in human peripheral blood mononuclear cells: correlation with alprazolam pharmacokinetics
    Isabella Gashaw
    Institute of Clinical Pharmacology, Charite University Medical Center, Humboldt University of Berlin, Berlin, Germany
    Clin Pharmacol Ther 74:448-57. 2003
    ..We also wanted to identify whether genetically determined high CYP3A5 expression is associated with increased alprazolam clearance...
  35. ncbi Pharmacogenetics-based new therapeutic concepts
    Ivar Roots
    Institut fur Klinische Pharmakologie, Charite Universitatsmedizin Berlin, Campus Charite Mitte, Humboldt Universitat zu Berlin, Berlin, Germany
    Drug Metab Rev 36:617-38. 2004
    ..g. receptor) also depends on genetic factors. In some cases genetic tests can help distinguish between responders and non-responders of a specific drug treatment. The first pharmacogenetic tests are already on the market...
  36. doi Baseline brain perfusion and the serotonin transporter promoter polymorphism
    Roberto Viviani
    Department of Psychiatry and Psychotherapy III, University of Ulm, Germany
    Biol Psychiatry 67:317-22. 2010
    ..We reassess the findings of an increased baseline perfusion in the amygdala and ventral prefrontal areas in healthy carriers of the risk genotype in a much larger sample than in previous studies...
  37. ncbi Trimipramine pharmacokinetics after intravenous and oral administration in carriers of CYP2D6 genotypes predicting poor, extensive and ultrahigh activity
    Julia Kirchheiner
    Institute of Clinical Pharmacology, University Medical Center Charite, Humboldt University of Berlin, Berlin
    Pharmacogenetics 13:721-8. 2003
    ..However, the effect of CYP2D6 genotype on steady state kinetics and on bioavailability has not been studied so far. In addition, we were interested in trimipramine pharmacokinetics in genetically defined ultra rapid metabolizers...
  38. ncbi Association of MDR1 genotypes with susceptibility to colorectal cancer in older non-smokers
    Elena Osswald
    Institute of Clinical Pharmacology, Charite Universitatsmedizin Berlin, Campus Mitte, Humboldt University of Berlin, Berlin, Germany
    Eur J Clin Pharmacol 63:9-16. 2007
    ..The importance of MDR1 SNPs 2677G > T/A in exon 21 and 3435C > T in exon 26 for cancer susceptibility, however, has not yet been clearly defined...
  39. ncbi Response to lithium augmentation in depression is associated with the glycogen synthase kinase 3-beta -50T/C single nucleotide polymorphism
    Mazda Adli
    Department of Psychiatry and Psychotherapy, Charite Universitatsmedizin Berlin, Campus Charite Mitte, Berlin, Germany
    Biol Psychiatry 62:1295-302. 2007
    ..This study investigates the association of the GSK3B -50T/C SNP and response to lithium augmentation in acutely depressed antidepressant nonresponders...
  40. ncbi The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment
    Jurgen Brockmoller
    Institute of Clinical Pharmacology, University Medical Center Charite, Humboldt University, Berlin, Germany
    Clin Pharmacol Ther 72:438-52. 2002
    ..The impact of the polymorphism on haloperidol pharmacokinetics, adverse events, and efficacy was prospectively evaluated under naturalistic conditions in 172 unselected psychiatric inpatients with acute psychotic symptoms...
  41. ncbi Rapid and simple method for the analysis of nateglinide in human plasma using HPLC analysis with UV detection
    Steffen Bauer
    Institute of Clinical Pharmacology, University Medical Center Charite, Humboldt University of Berlin, Schumannstr 20 21, 10098 Berlin, Germany
    J Pharm Biomed Anal 31:551-5. 2003
    ..Sample preparation time and analysis time are both short and allow rapid analysis of large sample sets...
  42. ncbi CYP2D6 ultrarapid metabolism and morphine/codeine ratios in blood: was it codeine or heroin?
    Y J He
    Institute of Pharmacology of Natural Products and Clinical Pharmacology, University of Ulm, Ulm, Germany
    J Anal Toxicol 32:178-82. 2008
    ..In urine, Mor/Cod ratios were below one for all EMs and UMs during the first 12 h. Thus, CYP2D6 genotyping in general will not explain Mor/Cod ratios > 1 in plasma or urine, unless the time of drug intake is more than 24 h previous...
  43. ncbi Pharmacogenetics-guided dose modifications of antidepressants
    Angela Seeringer
    Institute of Pharmacology of Natural Products and Clinical Pharmacology, University of Ulm, Helmholtzstrasse 20, 89081 Ulm, Germany
    Clin Lab Med 28:619-26. 2008
    ..In addition to antidepressive drugs, several drugs used in cancer therapy, beta-blockers, proton pump inhibitors, and opioid analgesics are metabolized by these enzymes...
  44. ncbi Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response
    J Kirchheiner
    Institute of Clinical Pharmacology, Campus Charite Mitte, University Medicine Berlin, Berlin, Germany
    Mol Psychiatry 9:442-73. 2004
    ....
  45. ncbi CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages
    J Kirchheiner
    Institute of Clinical Pharmacology, , Humboldt University of Berlin, Germany
    Acta Psychiatr Scand 104:173-92. 2001
    ..This is a first attempt to apply the new pharmacogenetics to suggest dose-regimens that take the differences in drug metabolic capacity into account...
  46. doi Sex-specific differences in side effects of psychotropic drugs: genes or gender?
    Sara Haack
    Institute of Pharmacology of Natural Products and Clinical Pharmacology, University Ulm, 89081 Ulm, Germany
    Pharmacogenomics 10:1511-26. 2009
    ..Clinicians should be made aware of the differences reported in the literature regarding the symptomatology, severity and recognition of the adverse psychotropic drug effects found in men and women...
  47. ncbi Simultaneous determination of celecoxib, hydroxycelecoxib, and carboxycelecoxib in human plasma using gradient reversed-phase liquid chromatography with ultraviolet absorbance detection
    Elke Störmer
    Institute of Clinical Pharmacology, University Medical Center Charite, Humboldt University Berlin, Schumannstrasse 20 21, 10098, Berlin, Germany
    J Chromatogr B Analyt Technol Biomed Life Sci 783:207-12. 2003
    ..9 to 14.2%. The achieved limits of quantitation (LOQ) of 10 ng/ml for each analyte allowed the determination of the pharmacokinetic parameters of the analytes after administration of 100 mg celecoxib...
  48. doi The role of clusterin, complement receptor 1, and phosphatidylinositol binding clathrin assembly protein in Alzheimer disease risk and cerebrospinal fluid biomarker levels
    Brit Maren M Schjeide
    Department Vertebrate Genomics, Max Planck Institute for Molecular Genetics, Berlin, Germany
    Arch Gen Psychiatry 68:207-13. 2011
    ..Despite their strong statistical support, all 3 signals emerged from heterogeneous case-control populations and lack replication in different settings...
  49. ncbi Individualized medicine - implementation of pharmacogenetic diagnostics in antidepressant drug treatment of major depressive disorders
    J Kirchheiner
    Institute of Clinical Pharmacology, Charite University Medicine Berlin, Campus Charité Mitte CCM, Berlin, Germany
    Pharmacopsychiatry 36:S235-43. 2003
    ....
  50. doi Genetic variants of the insulin receptor substrate-1 are influencing the therapeutic efficacy of oral antidiabetics
    A Seeringer
    Institute of Pharmacology of Natural Products and Clinical Pharmacology, University of Ulm, Ulm, Germany
    Diabetes Obes Metab 12:1106-12. 2010
    ..The Gly972Arg polymorphism in the insulin receptor substrate-1 (IRS-1) has been shown to play a role in insulin signal transduction and therapeutic failure to sulphonylurea drugs...
  51. ncbi Characterization of a functional promoter polymorphism of the human tryptophan hydroxylase 2 gene in serotonergic raphe neurons
    Kathrin Scheuch
    Laboratory of Molecular Psychiatry, Charite Universitatsmedizin Berlin, Schumannstrasse 20 21, Berlin, Germany
    Biol Psychiatry 62:1288-94. 2007
    ..Although dysfunction of 5-HT neurotransmission has been implicated in a variety of neuropsychiatric conditions, the human TPH2 promoter has not been characterized in vitro...
  52. ncbi Pharmacogenetic diagnostics of cytochrome P450 polymorphisms in clinical drug development and in drug treatment
    J Brockmoller
    Institute of Clinical Pharmacology, University Medical Center Charite, Humboldt University, Berlin, Germany
    Pharmacogenomics 1:125-51. 2000
    ..Those CYP alleles and polymorphically metabolised drugs which are currently most interesting in drug development and drug treatment are reviewed, and more complete information is available from websites cited in this article...
  53. ncbi [CYP2D6-, CYP2C9- and CYP2C19-based dose adjustments: when do they make sense?]
    A Seeringer
    Institut für Naturheilkunde und Klinische Pharmakologie, Universitat Ulm, Helmholtzstrasse 20, 89081 Ulm, Deutschland
    Internist (Berl) 49:877-83. 2008
    ..Especially for drugs with a narrow therapeutic index and a high risk for the development of adverse drug effects, genotyping could be helpful when choosing the right drug in the optimal dosage for individual patients...
  54. ncbi Atypical antipsychotics in severe anorexia nervosa in children and adolescents--review and case reports
    Claudia Mehler-Wex
    Department of Child and Adolescent Psychiatry Psychotherapy, University of Ulm, Steinhövelstr 5, Ulm, Germany
    Eur Eat Disord Rev 16:100-8. 2008
    ..To review the literature on the use of atypical antipsychotics in anorexia nervosa of children and adolescents and to present three case reports on quetiapine treatment of this subgroup...
  55. ncbi Thyroid, brain and mood modulation in affective disorder: insights from molecular research and functional brain imaging
    M Bauer
    Department of Psychiatry and Psychotherapy, Charite University Medicine Berlin, Campus Charité Mitte CCM, Berlin, Germany
    Pharmacopsychiatry 36:S215-21. 2003
    ..Theses studies confirm that thyroid hormones are active in modulating metabolic function in the mature adult brain, and provide intriging neuroanatomic clues that may guide future research...
  56. ncbi Re: modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4
    Leszek Wojnowski
    J Natl Cancer Inst 94:630-1; author reply 631-2. 2002
  57. ncbi Cytochrome P450 2C9 phenotyping using low-dose tolbutamide
    Alexander Jetter
    Department of Pharmacology, Clinical Pharmacology, University of Cologne, Gleueler Strasse 24, 50931 Cologne, Germany
    Eur J Clin Pharmacol 60:165-71. 2004
    ..However, therapeutically active doses of 500 mg bear the risk of hypoglycaemia, and a tolbutamide-derived parameter based on a single plasma or urine concentration reflecting CYP2C9 activity accurately is lacking...
  58. ncbi Serotonin syndrome with tramadol and citalopram
    Richard Mahlberg
    Am J Psychiatry 161:1129. 2004
  59. ncbi Workshop outcomes report: initiatives to establish a European Network of pharmacogenetics/genomics and progress
    Anke Hilse Maitland-van der Zee
    Division of Pharmacoepidemiology and Pharmacotherapy, Faculty of Science, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands
    Eur J Pharm Sci 31:151-5. 2007
  60. ncbi AmpliChip CYP450 GeneChip: a new gene chip that allows rapid and accurate CYP2D6 genotyping
    Tanja Heller
    Department of Clinical Chemistry, Georg August University Gottingen, Robert Koch Str 40, 37099 Gottingen, Germany
    Ther Drug Monit 28:673-7. 2006
    ..It therefore represents a very efficient and fast method, offering new perspectives for the application of pharmacogenetics in clinical medicine...
  61. pmc Translating pharmacogenomics: challenges on the road to the clinic
    Jesse J Swen
    Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands
    PLoS Med 4:e209. 2007
    ..This article presents specific clinical examples of such challenges and discusses how obstacles to implementation of pharmacogenomic testing can be addressed...
  62. ncbi Assessment of urinary mephenytoin metrics to phenotype for CYP2C19 and CYP2B6 activity
    Tobias Klaassen
    Department of Pharmacology, Clinical Pharmacology, Hospital of the University of Cologne, Gleueler Str 24, 50931, Koln, Germany
    Eur J Clin Pharmacol 64:387-98. 2008
    ..We also assessed whether urinary excretion of N-desmethylmephenytoin (nirvanol) might be a useful CYP2B6 metric in in vivo studies...
  63. ncbi Association of CYP2D6 genotypes and personality traits in healthy individuals
    Julia Kirchheiner
    J Clin Psychopharmacol 26:440-2. 2006
  64. ncbi Clinical consequences of cytochrome P450 2C9 polymorphisms
    Julia Kirchheiner
    Department of Pharmacology, University of Cologne, 50931 Koln, Germany
    Clin Pharmacol Ther 77:1-16. 2005
    ..However, our current understanding of the role of CYP2C9 in biotransformation of endogenous signaling molecules and in drug toxicity is relatively meager...
  65. ncbi CYP2C9 polymorphisms and the interindividual variability in pharmacokinetics and pharmacodynamics of the loop diuretic drug torsemide
    Stefan Viktor Vormfelde
    Department of Clinical Pharmacology, University Medical Cenger, Georg August University Gottingen, 37075 Gottingen, Germany
    Clin Pharmacol Ther 76:557-66. 2004
    ....
  66. ncbi Effects of fluvastatin and cigarette smoking on CYP2C9 activity measured using the probe S-warfarin
    Myong Jin Kim
    Clinical Pharmacology Research Center, Bassett Healthcare, One Atwell Road, Cooperstown, NY 13326 1394, USA
    Eur J Clin Pharmacol 62:431-6. 2006
    ..In addition, the effect of the CYP2C9 inhibitor fluvastatin was evaluated using S-warfarin as a probe...
  67. ncbi Pharmacogenetics-based therapeutic recommendations--ready for clinical practice?
    Julia Kirchheiner
    Department of Pharmacology, University of Cologne, Gleueler Strasse 24, 50931, Koln, Germany
    Nat Rev Drug Discov 4:639-47. 2005
    ..Here, we argue for the development of concise guidelines for implementation of PGx analyses in drug development and therapy...
  68. doi Hepatic nuclear factor 1alpha inhibitor ursodeoxycholic acid influences pharmacokinetics of the organic anion transporting polypeptide 1B1 substrate rosuvastatin and bilirubin
    Yi Jing He
    Pharmacogenetics Research Institute, Institute of Clinical Pharmacology, Central South University, Changsha, Hunan 410078, China
    Drug Metab Dispos 36:1453-6. 2008
    ..They highlight a novel mechanism of OATP1B1-based interaction that is mediated by transcription factor HNF1alpha...
  69. doi Common genetic variations in human brain-specific tryptophan hydroxylase-2 and response to antidepressant treatment
    Mladen Vassilev Tzvetkov
    Department of Clinical Pharmacology, Georg August University, Gottingen, Germany
    Pharmacogenet Genomics 18:495-506. 2008
    ..In this study, we analyzed the correlation between TPH2 polymorphisms and response to antidepressant drugs...